132
Participants
Start Date
June 27, 2018
Primary Completion Date
December 30, 2024
Study Completion Date
December 30, 2024
CAB-ROR2-ADC
Conditionally active biologic anti-ROR2 antibody drug conjugate
PD-1 inhibitor
PD-1 inhibitor
NYU Langone Health, New York
Columbia University Medical Center, New York
HENRY DUNANT Hospital Center, 4th Department of Medical Oncology and Clinical Trials Unit, Athens
Roswell Park, Buffalo
UPMC Cancer Center, Pittsburgh
"Metropolitan Hospital Perseus Healthcare Group SA 4th Oncology Department", Piraeus
Wake Forest Baptist Health, Winston-Salem
University Clinic of Navarra - Madrid, Madrid
University Hospital 12 de Octubre, Madrid
FirstHealth Outpatient Cancer Center, Pinehurst
Medical University of South Carolina- Hollings Cancer Center, Charleston
Augusta University - Georgia Cancer Center, Augusta
Florida Cancer Specialists & Research Institute, Fleming Island
Memorial Cancer Institute (MCI), Hollywood
Florida Cancer Specialists, West Palm Beach
Memorial Sloan-Kettering Cancer Center, Tampa
Moffitt Cancer Center, Tampa
Florida Cancer Specialists & Research Institute, Fort Myers
Florida Cancer Specialist - North, St. Petersburg
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Brownsboro Hospital Campus, Louisville
Baptist Health Systems, Lexington
University of Kentucky, Lexington
University Hospital Nuestra Senora de Valme, Seville
The Christ Hospital, Cincinnati
Bioclinic Thessaloniki, Οncology Department, Thessaloniki
European Interbalkan Medical Center, Οncology Department, Thessaloniki
Hematology/Oncology Clinic, Baton Rouge
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center, Houston
University of Colorado, Aurora
Sarah Cannon Research Institute at Health One, Denver
University of Utah - Huntsman Cancer Institute, Salt Lake City
University of Arizona Cancer Center, Tucson
Comprehensive Cancer Care of Nevada, Las Vegas
OptumCare Cancer Care, Las Vegas
California Research Institute, Los Angeles
USC Norris, Los Angeles
American Institute of Research, Whittier
City of Hope - Duarte, Duarte
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
UC Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange
University of California San Francisco, San Francisco
Oregon Health & Science University, Portland
Dana-Farber Cancer Institute, Boston
Prince of Wales Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
National Cheng Kung University Hospital, Tainan City
National Taiwan University Hospital, Taipei
LinKou Chang Gung Memorial Hospital, Taoyuan
MED-Polonia, Sp. z o.o. (LLC), Poznan
Institute of Genetics and Immunology GENIM LCC in Lublin, Lublin
Malgorzata Kozlik, Warsaw
Polish Mother's Memorial Hospital-Research Institute, Lodz
Beata Głogowska, Tomaszów Mazowiecki
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital del Mar, Barcelona
Anna Ramos Luna, Barcelona
Lead Sponsor
BioAtla, Inc.
INDUSTRY